GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunogen Inc (NAS:IMGN) » Definitions » ROE %

Immunogen (Immunogen) ROE % : 23.37% (As of Sep. 2023)


View and export this data going back to 1989. Start your Free Trial

What is Immunogen ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Immunogen's annualized net income for the quarter that ended in Sep. 2023 was $123.0 Mil. Immunogen's average Total Stockholders Equity over the quarter that ended in Sep. 2023 was $526.2 Mil. Therefore, Immunogen's annualized ROE % for the quarter that ended in Sep. 2023 was 23.37%.

The historical rank and industry rank for Immunogen's ROE % or its related term are showing as below:

IMGN' s ROE % Range Over the Past 10 Years
Min: -659.86   Med: -82.43   Max: -24.37
Current: -24.37

During the past 13 years, Immunogen's highest ROE % was -24.37%. The lowest was -659.86%. And the median was -82.43%.

IMGN's ROE % is not ranked
in the Biotechnology industry.
Industry Median: -44.1 vs IMGN: -24.37

Immunogen ROE % Historical Data

The historical data trend for Immunogen's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunogen ROE % Chart

Immunogen Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -659.86 -67.11 -92.61

Immunogen Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -145.39 -141.41 -118.13 -5.55 23.37

Competitive Comparison of Immunogen's ROE %

For the Biotechnology subindustry, Immunogen's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immunogen's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunogen's ROE % distribution charts can be found below:

* The bar in red indicates where Immunogen's ROE % falls into.



Immunogen ROE % Calculation

Immunogen's annualized ROE % for the fiscal year that ended in Dec. 2022 is calculated as

ROE %=Net Income (A: Dec. 2022 )/( (Total Stockholders Equity (A: Dec. 2021 )+Total Stockholders Equity (A: Dec. 2022 ))/ count )
=-222.929/( (325.586+155.826)/ 2 )
=-222.929/240.706
=-92.61 %

Immunogen's annualized ROE % for the quarter that ended in Sep. 2023 is calculated as

ROE %=Net Income (Q: Sep. 2023 )/( (Total Stockholders Equity (Q: Jun. 2023 )+Total Stockholders Equity (Q: Sep. 2023 ))/ count )
=122.992/( (490.842+561.596)/ 2 )
=122.992/526.219
=23.37 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2023) net income data. ROE % is displayed in the 30-year financial page.


Immunogen  (NAS:IMGN) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Sep. 2023 )
=Net Income/Total Stockholders Equity
=122.992/526.219
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(122.992 / 453.7)*(453.7 / 768.214)*(768.214 / 526.219)
=Net Margin %*Asset Turnover*Equity Multiplier
=27.11 %*0.5906*1.4599
=ROA %*Equity Multiplier
=16.01 %*1.4599
=23.37 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Sep. 2023 )
=Net Income/Total Stockholders Equity
=122.992/526.219
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (122.992 / 118.328) * (118.328 / 103.824) * (103.824 / 453.7) * (453.7 / 768.214) * (768.214 / 526.219)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.0394 * 1.1397 * 22.88 % * 0.5906 * 1.4599
=23.37 %

Note: The net income data used here is four times the quarterly (Sep. 2023) net income data. The Revenue data used here is four times the quarterly (Sep. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Immunogen ROE % Related Terms

Thank you for viewing the detailed overview of Immunogen's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Immunogen (Immunogen) Business Description

Traded in Other Exchanges
Address
830 Winter Street, Waltham, MA, USA, 02451
Immunogen Inc is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent.
Executives
Theresa Wingrove officer: VP of Regulatory Affairs IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Renee Lentini officer: V.P.-Fin., Prin. Acctg. Off. 830 WINTER STREET, WALTHAM MA 02451
Stacy Ann Coen officer: Chief Business Officer 11 RUSH POND RD, LAKEVILLE MA 02347
Kristine Peterson director AMARIN CORPORATION, MYSTIC PACKER BLDG., 12 ROOSEVELT AVENUE, MYSTIC CT 06355
Lauren White officer: SVP, CFO and PFO C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Mark J Enyedy director, officer: Chief Executive Officer C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Isabel Kalofonos officer: SVP & CHIEF COMMERCIAL OFFICER C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Michael Vasconcelles officer: EVP R&D & MEDICAL AFFAIRS C/O UNUM THERAPEUTICS, 200 CAMBRIDGEPARK DR., STE. 3100, CAMBRIDGE MA 02140
Daniel Char officer: SVP & CHIEF LEGAL OFFICER C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Kristen Harrington-smith officer: SVP & Chief Commercial Officer C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Tracey L Mccain director C/O BLUEPRINTS MEDICINES CORPORATION, 38 SIDNEY STREET, SUITE 200, CAMBRIDGE MA 02139
Helen M. Thackray director C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
David G Foster officer: V.P.-Fin., Prin. Acctg. Off. C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Susan Altschuller officer: SVP and CFO 45 TENNYSON ST., SOMERVILLE MA 02145
Craig Barrows officer: Vice-President,General Counsel C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451